This image will be automatically disabled when it gets reported by several people.
Australian firm to start trials of bird flu vaccine 2 Canberra "In an emergency, if the dose that we tested was successful and the strain remains the same, it would take us three months to produce 40 million doses. We would start to get the product
Aventis, which has proved effective at stimulating an immune system response in healthy adults. "That used an enormous dose of antigen. In fact, the dose of antigen was so large that we wouldn't even go down that path because it would just take too long to make," David said. Antigen is the key vaccine component that triggers an immune response. "Essentially we are all sharing information so that whoever comes up with the preferred process can share the information as quickly as possible." U.S.-based Chiron Corp. aims to test its H5N1 vaccine later this year and Britain's GlaxoSmithKline Plc plans large-scale clinical trials in 2006. The Australian government reissued a flood of travel warnings for Asia to alert Australians to the bird flu outbreak. The H5N1 strain first emerged in Hong Kong in 1997, where it killed six people, and surfaced again on the Korean peninsula in 2003. It has since been found in birds in Cambodia, China, Indonesia, Japan, Kazakhstan, Laos, Malaysia, Mongolia, Philippines, Russia, Taiwan, Thailand and Vietnam. --SP 1331 Local Time 1031 GMT
